“CRISPR 3.0: FDA Approves First In-Vivo Gene Editing for Cholesterol Management”
BOSTON — Verve Therapeutics’ single-injection therapy, EDIT-101, permanently disables the PCSK9 gene in human trials, slashing LDL cholesterol by 75%. Priced at $450,000, the treatment sparks ethical debates over “designer biology” accessibility… Covers insurance industry backlash and WHO equity guidelines.